67,139 Shares in Horizon Therapeutics PLC (HZNP) Purchased by Laurion Capital Management LP

Laurion Capital Management LP purchased a new stake in Horizon Therapeutics PLC (NASDAQ:HZNP) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 67,139 shares of the biopharmaceutical company’s stock, valued at approximately $1,774,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in HZNP. Daiwa Securities Group Inc. acquired a new position in shares of Horizon Therapeutics during the 1st quarter worth approximately $29,000. Private Capital Group LLC grew its position in shares of Horizon Therapeutics by 141.5% during the 4th quarter. Private Capital Group LLC now owns 1,963 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,150 shares in the last quarter. Quadrant Capital Group LLC acquired a new position in shares of Horizon Therapeutics during the 1st quarter worth approximately $53,000. Quantamental Technologies LLC acquired a new position in shares of Horizon Therapeutics during the 1st quarter worth approximately $88,000. Finally, SG Americas Securities LLC grew its position in shares of Horizon Therapeutics by 79.5% during the 4th quarter. SG Americas Securities LLC now owns 9,438 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 4,179 shares in the last quarter. Institutional investors and hedge funds own 83.32% of the company’s stock.

Shares of Horizon Therapeutics stock opened at $25.95 on Wednesday. Horizon Therapeutics PLC has a 1-year low of $14.89 and a 1-year high of $29.44. The company has a quick ratio of 1.97, a current ratio of 1.74 and a debt-to-equity ratio of 0.90. The company has a market cap of $4.68 billion, a PE ratio of 14.18 and a beta of 1.09.

Horizon Therapeutics (NASDAQ:HZNP) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $0.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.10 by $0.20. The business had revenue of $280.00 million during the quarter, compared to the consensus estimate of $238.35 million. Horizon Therapeutics had a net margin of 3.79% and a return on equity of 33.57%. The firm’s revenue was up 25.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.03 EPS. On average, research analysts forecast that Horizon Therapeutics PLC will post 1.64 earnings per share for the current year.

In related news, EVP Geoffrey M. Curtis sold 10,080 shares of the stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $21.21, for a total value of $213,796.80. Following the completion of the transaction, the executive vice president now owns 35,367 shares of the company’s stock, valued at approximately $750,134.07. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.10% of the stock is owned by corporate insiders.

A number of research analysts have issued reports on HZNP shares. BidaskClub lowered shares of Horizon Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, April 19th. Morgan Stanley upgraded shares of Horizon Therapeutics from an “equal weight” rating to an “overweight” rating and set a $32.00 target price on the stock in a research report on Friday, March 8th. Mizuho restated a “neutral” rating and set a $27.00 target price on shares of Horizon Therapeutics in a research report on Friday, March 1st. Finally, JMP Securities upped their price target on shares of Horizon Therapeutics from $26.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, March 1st. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Horizon Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $30.83.

TRADEMARK VIOLATION NOTICE: “67,139 Shares in Horizon Therapeutics PLC (HZNP) Purchased by Laurion Capital Management LP” was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/22/67139-shares-in-horizon-therapeutics-plc-hznp-purchased-by-laurion-capital-management-lp.html.

Horizon Therapeutics Profile

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Read More: What is the Consumer Price Index (CPI)?

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Therapeutics (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.